Variable . | Early-onset . | . | . | Usual onset . | . | . | ||||
---|---|---|---|---|---|---|---|---|---|---|
. | Type 2 diabetic patients . | Control subjects . | HR (95% CI)* . | Type 2 diabetic patients . | Control subjects . | HR (95% CI)* . | ||||
n | 1,600 | 1,600 | 6,244 | 6,244 | ||||||
MI pre/at diagnosis (%) | 0.8 | 0.4 | 13.0 | 7.3 | ||||||
MI after diagnosis (%)† | 4.6 | 1.2 | 14.0 (6.2–31.4) | 23.4 | 12.2 | 3.7 (3.2–4.2) | ||||
Stroke pre/at diagnosis (%) | 0.3 | 0.3 | 3.7 | 2.3 | ||||||
Stroke after diagnosis (%)† | 1.6 | 0.6 | 30.1 (6.0–152.1) | 11.1 | 6.5 | 3.1 (2.7–3.7) | ||||
CABG pre/at diagnosis (%) | 0 | 0 | 0.5 | 0.5 | ||||||
CABG after diagnosis (%) | 0.8 | 0.2 | ‡ | 3.8 | 2.0 | 3.1 (2.5–4.0) | ||||
PTCA pre/at diagnosis (%) | 0.1 | 0 | 0.3 | 0.1 | ||||||
PTCA after diagnosis (%) | 1.0 | 0.3 | 6.5 (2.1–20.3) | 1.9 | 1.1 | 3.5 (2.5–5.0) | ||||
PVD pre/at diagnosis (%) | 0.3 | 0.1 | 2.1 | 1.3 | ||||||
PVD after diagnosis (%) | 1.6 | 0.8 | 3.6 (1.7–7.9) | 9.1 | 4.0 | 4.2 (3.5–5.1) | ||||
Any macrovascular complication§ pre/at diagnosis (%) | 1.3 | 0.7 | 16.2 | 9.5 | ||||||
Any macrovascular complication§ after diagnosis (%)† | 7.0 | 2.5 | 7.9 (4.8–13.0) | 34.3 | 18.5 | 3.8 (3.4–4.2) |
Variable . | Early-onset . | . | . | Usual onset . | . | . | ||||
---|---|---|---|---|---|---|---|---|---|---|
. | Type 2 diabetic patients . | Control subjects . | HR (95% CI)* . | Type 2 diabetic patients . | Control subjects . | HR (95% CI)* . | ||||
n | 1,600 | 1,600 | 6,244 | 6,244 | ||||||
MI pre/at diagnosis (%) | 0.8 | 0.4 | 13.0 | 7.3 | ||||||
MI after diagnosis (%)† | 4.6 | 1.2 | 14.0 (6.2–31.4) | 23.4 | 12.2 | 3.7 (3.2–4.2) | ||||
Stroke pre/at diagnosis (%) | 0.3 | 0.3 | 3.7 | 2.3 | ||||||
Stroke after diagnosis (%)† | 1.6 | 0.6 | 30.1 (6.0–152.1) | 11.1 | 6.5 | 3.1 (2.7–3.7) | ||||
CABG pre/at diagnosis (%) | 0 | 0 | 0.5 | 0.5 | ||||||
CABG after diagnosis (%) | 0.8 | 0.2 | ‡ | 3.8 | 2.0 | 3.1 (2.5–4.0) | ||||
PTCA pre/at diagnosis (%) | 0.1 | 0 | 0.3 | 0.1 | ||||||
PTCA after diagnosis (%) | 1.0 | 0.3 | 6.5 (2.1–20.3) | 1.9 | 1.1 | 3.5 (2.5–5.0) | ||||
PVD pre/at diagnosis (%) | 0.3 | 0.1 | 2.1 | 1.3 | ||||||
PVD after diagnosis (%) | 1.6 | 0.8 | 3.6 (1.7–7.9) | 9.1 | 4.0 | 4.2 (3.5–5.1) | ||||
Any macrovascular complication§ pre/at diagnosis (%) | 1.3 | 0.7 | 16.2 | 9.5 | ||||||
Any macrovascular complication§ after diagnosis (%)† | 7.0 | 2.5 | 7.9 (4.8–13.0) | 34.3 | 18.5 | 3.8 (3.4–4.2) |
HRs are obtained from Cox proportional hazards model and adjusted for sex and length of follow-up. Only subjects who did not have the complication at diagnosis are included in the analyses.
95% CIs do not overlap between early- and usual-onset groups.
Due to small number of CABG events in control subjects, HR can not be calculated.
Any macrovascular event is any of the above complications.